Dr. Jack West reviews the new FDA approval for afatinib (Gilotrif) for specific uncommon EGFR mutations, including G719X, L861Q, and S768I, in advanced NSCLC.
A New Treatment Option for Uncommon EGFR Mutations (BMIC-023)
Advertisement
[the_ad id="32629"]